North America Cardiac Rhythm Management Market Outlook to … · Page 1 North America Cardiac Rhythm Management Market Outlook to 2020 Reference Code: GDMECR0090DB ... 9.2 Financial

North America Cardiac Rhythm Management Market Outlook to 2020 GDMECR0090DB / Published May 2014

© GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form

Page 1

North America Cardiac Rhythm

Management Market Outlook to 2020

Reference Code: GDMECR0090DB

Publication Date: May 2014



Page 2

1 Table of Contents

1 Table of Contents .................................................................................................................................................... 2

1.1 List of Tables .................................................................................................................................................... 7

1.2 List of Figures ................................................................................................................................................... 8

2 Introduction ............................................................................................................................................................ 11

2.1 What Is This Report About? ........................................................................................................................... 11

2.2 Cardiac Rhythm Management Market Segmentation .................................................................................... 11

2.3 Definitions of Markets Covered in the Report ................................................................................................ 12

3 Cardiac Rhythm Management Market, North America ...................................................................................... 14

3.1 Cardiac Rhythm Management Market, North America, Revenue ($m), 2005-2020 ...................................... 14

3.2 Cardiac Rhythm Management Market, North America, Category Comparison by Revenue ($m), 2005-2020 16



3.5 Cardiac Rhythm Management Market, North America, Volume (Units), 2005-2020 ..................................... 22



3.8 Cardiac Rhythm Management Market, North America, Company Share by Revenue ($m), 2011-2012 ...... 28

4 Cardiac Rhythm Management Market, Canada .................................................................................................. 30

4.1 Cardiac Rhythm Management Market, Canada, Revenue ($m), 2005-2012 ................................................ 30

4.2 Cardiac Rhythm Management Market, Canada, Revenue ($m), 2012-2020 ................................................ 32

4.2.1 Cardiac Resynchronisation Therapy Market, Canada, Revenue ($m), by Segment, 2005-2012.............. 34

4.2.2 Implantable Cardioverter Defibrillators Market, Canada, Revenue ($m), by Segment, 2005-2012 .......... 36

4.2.3 Pacemakers Market, Canada, Revenue ($m), by Segment, 2005-2012 ................................................... 38

4.2.4 Cardiac Resynchronisation Therapy Market, Canada, Revenue ($m), by Segment, 2012-2020.............. 40

4.2.5 Implantable Cardioverter Defibrillators Market, Canada, Revenue ($m), by Segment, 2012-2020 .......... 42

4.2.6 Pacemakers Market, Canada, Revenue ($m), by Segment, 2012-2020 ................................................... 44

4.3 Cardiac Rhythm Management Market, Canada, Volume (Units), 2005-2012 ............................................... 46

4.4 Cardiac Rhythm Management Market, Canada, Volume (Units), 2012-2020 ............................................... 48

4.4.1 Cardiac Resynchronisation Therapy Market, Canada, Volume (Units), by Segment, 2005-2012............. 50

4.4.2 Implantable Cardioverter Defibrillators Market, Canada, Volume (Units), by Segment, 2005-2012 ......... 52

4.4.3 Pacemakers Market, Canada, Volume (Units), by Segment, 2005-2012 .................................................. 54

4.4.4 Cardiac Resynchronisation Therapy Market, Canada, Volume (Units), by Segment, 2012-2020............. 56

4.4.5 Implantable Cardioverter Defibrillators Market, Canada, Volume (Units), by Segment, 2012-2020 ......... 58

4.4.6 Pacemakers Market, Canada, Volume (Units), by Segment, 2012-2020 .................................................. 60

4.5 Cardiac Rhythm Management Market, Canada, Average Price ($), 2005-2020 ........................................... 62

4.6 Cardiac Rhythm Management Market, Canada, Distribution Share by Revenue ($m), 2011-2012 .............. 64

4.7 Cardiac Rhythm Management Market, Canada, Company Share by Revenue ($m), 2011-2012 ................ 65

5 Cardiac Rhythm Management Market, Mexico ................................................................................................... 67

5.1 Cardiac Rhythm Management Market, Mexico, Revenue ($m), 2005-2012.................................................. 67



Page 3

5.2 Cardiac Rhythm Management Market, Mexico, Revenue ($m), 2012-2020.................................................. 69

5.2.1 Cardiac Resynchronisation Therapy Market, Mexico, Revenue ($m), by Segment, 2005-2012 ............... 71

5.2.2 Implantable Cardioverter Defibrillators Market, Mexico, Revenue ($m), by Segment, 2005-2012............ 73

5.2.3 Pacemakers Market, Mexico, Revenue ($m), by Segment, 2005-2012 .................................................... 75

5.2.4 Cardiac Resynchronisation Therapy Market, Mexico, Revenue ($m), by Segment, 2012-2020 ............... 77

5.2.5 Implantable Cardioverter Defibrillators Market, Mexico, Revenue ($m), by Segment, 2012-2020............ 79

5.2.6 Pacemakers Market, Mexico, Revenue ($m), by Segment, 2012-2020 .................................................... 81

5.3 Cardiac Rhythm Management Market, Mexico, Volume (Units), 2005-2012 ................................................ 83

5.4 Cardiac Rhythm Management Market, Mexico, Volume (Units), 2012-2020 ................................................ 85

5.4.1 Cardiac Resynchronisation Therapy Market, Mexico, Volume (Units), by Segment, 2005-2012 .............. 87

5.4.2 Implantable Cardioverter Defibrillators Market, Mexico, Volume (Units), by Segment, 2005-2012........... 89

5.4.3 Pacemakers Market, Mexico, Volume (Units), by Segment, 2005-2012 ................................................... 91

5.4.4 Cardiac Resynchronisation Therapy Market, Mexico, Volume (Units), by Segment, 2012-2020 .............. 93

5.4.5 Implantable Cardioverter Defibrillators Market, Mexico, Volume (Units), by Segment, 2012-2020........... 95

5.4.6 Pacemakers Market, Mexico, Volume (Units), by Segment, 2012-2020 ................................................... 97

5.5 Cardiac Rhythm Management Market, Mexico, Average Price ($), 2005-2020 ............................................ 99

5.6 Cardiac Rhythm Management Market, Mexico, Distribution Share by Revenue ($m), 2011-2012 ............. 101

5.7 Cardiac Rhythm Management Market, Mexico, Company Share by Revenue ($m), 2011-2012 ............... 102

6 Cardiac Rhythm Management Market, United States ...................................................................................... 104

6.1 Cardiac Rhythm Management Market, United States, Revenue ($m), 2005-2012 ..................................... 104

6.2 Cardiac Rhythm Management Market, United States, Revenue ($m), 2012-2020 ..................................... 106

6.2.1 Cardiac Resynchronisation Therapy Market, United States, Revenue ($m), by Segment, 2005-2012 .. 108

6.2.2 Implantable Cardioverter Defibrillators Market, United States, Revenue ($m), by Segment, 2005-2012 110

6.2.3 Pacemakers Market, United States, Revenue ($m), by Segment, 2005-2012 ........................................ 112

6.2.4 Cardiac Resynchronisation Therapy Market, United States, Revenue ($m), by Segment, 2012-2020 .. 114

6.2.5 Implantable Cardioverter Defibrillators Market, United States, Revenue ($m), by Segment, 2012-2020 116

6.2.6 Pacemakers Market, United States, Revenue ($m), by Segment, 2012-2020 ........................................ 118

6.3 Cardiac Rhythm Management Market, United States, Volume (Units), 2005-2012 .................................... 120

6.4 Cardiac Rhythm Management Market, United States, Volume (Units), 2012-2020 .................................... 122

6.4.1 Cardiac Resynchronisation Therapy Market, United States, Volume (Units), by Segment, 2005-2012 . 124

6.4.2 Implantable Cardioverter Defibrillators Market, United States, Volume (Units), by Segment, 2005-2012 126

6.4.3 Pacemakers Market, United States, Volume (Units), by Segment, 2005-2012 ....................................... 128

6.4.4 Cardiac Resynchronisation Therapy Market, United States, Volume (Units), by Segment, 2012-2020 . 130

6.4.5 Implantable Cardioverter Defibrillators Market, United States, Volume (Units), by Segment, 2012-2020 132

6.4.6 Pacemakers Market, United States, Volume (Units), by Segment, 2012-2020 ....................................... 134

6.5 Cardiac Rhythm Management Market, United States, Average Price ($), 2005-2020 ................................ 136

6.6 Cardiac Rhythm Management Market, United States, Distribution Share by Revenue ($m), 2011-2012 ... 138

6.7 Cardiac Rhythm Management Market, United States, Company Share by Revenue ($m), 2011-2012 ..... 139

7 Overview of Key Companies in North America Cardiac Rhythm Management Market ............................... 141



Page 4

7.1 Medtronic, Inc. .............................................................................................................................................. 141

7.1.1 Company Overview .................................................................................................................................. 141

7.2 St. Jude Medical, Inc. ................................................................................................................................... 141


7.3 Boston Scientific Corporation ....................................................................................................................... 141


7.4 Biotronik SE & Co. KG ................................................................................................................................. 142


7.5 Sorin S.p.A. .................................................................................................................................................. 142


8 Cardiac Rhythm Management Market Pipeline Products ................................................................................ 143

9 Recent Developments ......................................................................................................................................... 144

9.1 Corporate Communications ......................................................................................................................... 144

9.1.1 Apr 16, 2014: Proteus Digital Health Grows Leadership Team and Board of Directors with Former Executives from Novartis, Microsoft and Egreetings Network............................................................................... 144

9.1.2 Apr 08, 2014: Ventripoint Corporate Update and Resignation of Director ............................................... 144

9.1.3 Feb 18, 2014: SurModics Announces Changes to Board of Directors .................................................... 145

9.1.4 Feb 14, 2014: Stereotaxis Appoints William C. Mills III to Chief Executive Officer ................................. 146

9.1.5 Jan 06, 2014: Catalyst Pharmaceutical Partners Reports Successful Completion of Type B Breakthrough Therapy Meeting With FDA on Firdapse Tablets Development Program ............................................................. 146

9.1.6 Dec 05, 2013: Anxious Patient Group Calls on NICE to Approve Only Drug Treatment for Ultra-Rare Disease 148

9.1.7 Nov 04, 2013: Canbex Therapeutics Commences Phase I Clinical Trial of Lead Product VSN16R as a Potential Treatment for Spasticity in Multiple Sclerosis ......................................................................................... 150

9.1.8 Sep 25, 2013: Accellent Announces the Promotion of Jeremy Friedman to President and Chief Operating Officer for the Cardio & Vascular Business and the Appointment of Richard Johnson as Interim CFO ............... 150

9.1.9 Sep 20, 2013: SurModics Announces Board Changes............................................................................ 151

9.1.10 Sep 16, 2013: Arena Pharmaceuticals Provides Update as Eisai's Launch of BELVIQ CIV Enters Consumer Phase ................................................................................................................................................... 151

9.1.11 Aug 19, 2013: Orthofix Receives Expected NASDAQ Notice Related to Late Filing of Form 10-Q .... 152

9.1.12 Aug 16, 2013: Stereotaxis Announces Listing Transfer to NASDAQ Capital Market .......................... 152

9.1.13 Aug 02, 2013: China CDC Enters Into R&D Agreement With Aeras Global For TB Vaccine .............. 152

9.1.14 Jul 23, 2013: Dean Schauer, Executive Vice President, Cardio & Vascular Group, Announces Resignation ............................................................................................................................................................ 154

9.1.15 Jul 02, 2013: InSite Vision Receives Notice of Allowance from USPTO for Patent on DuraSite 2 Ophthalmic Drug Delivery System ......................................................................................................................... 154

9.2 Financial Announcements ............................................................................................................................ 155

9.2.1 May 06, 2014: Stereotaxis Reports 2014 First Quarter Financial Results ............................................... 155

9.2.2 May 01, 2014: SurModics Reports Second Quarter Fiscal 2014 Results ................................................ 156

9.2.3 Apr 22, 2014: Bard Announces First Quarter Results .............................................................................. 158

9.2.4 Feb 25, 2014: Stereotaxis Reports 2013 Fourth Quarter and Full Year Financial Results ..................... 158

9.2.5 Feb 18, 2014: Medtronic Reports Third Quarter Earnings ....................................................................... 160

9.2.6 Jan 30, 2014: Bard Announces Fourth Quarter Results .......................................................................... 162



Page 5

9.2.7 Jan 30, 2014: SurModics Reports First Quarter Fiscal 2014 Results ...................................................... 162

9.2.8 Dec 11, 2013: Bard Declares Quarterly Dividend .................................................................................... 164

9.2.9 Nov 19, 2013: Medtronic Reports Second Quarter Earnings................................................................... 164

9.2.10 Nov 14, 2013: Stereotaxis Reports Third Quarter 2013 Financial Results .......................................... 166

9.2.11 Nov 11, 2013: Medtronic to Announce Financial Results for Its Second Quarter of Fiscal Year 2014 167

9.2.12 Nov 07, 2013: Accellent Announces Third Quarter 2013 Results ....................................................... 168

9.2.13 Nov 05, 2013: SurModics Reports Fourth Quarter and Full Year 2013 Results .................................. 169

9.2.14 Oct 29, 2013: SurModics to Webcast Fourth Quarter and Fiscal Year 2013 Earnings Conference Call on November 5 ...................................................................................................................................................... 171

9.2.15 Oct 23, 2013: Stereotaxis Announces Preliminary Third Quarter 2013 Financial Results in Preparation for Rights Offering .................................................................................................................................................. 171

9.2.16 Oct 22, 2013: Bard Announces Third Quarter Results ........................................................................ 172

9.2.17 Oct 09, 2013: Bard Declares Quarterly Dividend ................................................................................. 172

9.2.18 Oct 01, 2013: Bard to Host Earnings Conference Call on October 22, 2013 ...................................... 172

9.2.19 Aug 20, 2013: Medtronic Reports First Quarter Earnings .................................................................... 173

9.2.20 Aug 13, 2013: Accellent Announces Second Quarter 2013 Results ................................................... 174

9.2.21 Aug 12, 2013: Medtronic to Announce Financial Results for Its First Quarter of Fiscal Year 2014 .... 176

9.2.22 Aug 08, 2013: Stereotaxis Reports Second Quarter 2013 Financial Results; Announces Capital Transactions .......................................................................................................................................................... 176

9.2.23 Aug 06, 2013: Accellent Announces Timing of Second Quarter 2013 Earnings Release and Conference Call ..................................................................................................................................................... 178

9.2.24 Jul 31, 2013: SurModics Reports Third Quarter Fiscal 2013 Results .................................................. 178

9.2.25 Jul 24, 2013: Bard Announces Second Quarter Results ..................................................................... 180

9.2.26 Jul 23, 2013: SurModics to Webcast Third Quarter 2013 Earnings Conference Call on July 31 ........ 181

9.2.27 May 21, 2013: Medtronic Reports Revenue Of $16.6 Billion In Fiscal 2013 ....................................... 181

9.2.28 May 14, 2013: Accellent Reports Revenue Of $120.8m In Q1 2013 ................................................... 183

9.3 Government and Public Interest ................................................................................................................... 183

9.3.1 Jan 06, 2014: Medtronic CEO Omar Ishrak to Speak at J.P. Morgan Healthcare Conference ............... 183

9.3.2 Jan 06, 2014: Bard to Host Earnings Conference Call on January 30, 2014 .......................................... 183

9.3.3 Dec 20, 2013: Bard to Present at J.P. Morgan Healthcare Conference .................................................. 183

9.3.4 Dec 06, 2013: Stereotaxis to Present at Oppenheimer 24th Annual Healthcare Conference in New York on December 11, 2013 .......................................................................................................................................... 183

9.3.5 Dec 04, 2013: SurModics to Present at Oppenheimer Healthcare Conference ...................................... 184

9.3.6 Dec 04, 2013: Medtronic CFO Gary Ellis to Speak at Oppenheimer Healthcare Conference ................ 184

9.3.7 Nov 26, 2013: SurModics to Present at Piper Jaffray Healthcare Conference ........................................ 184

9.3.8 Nov 26, 2013: Medtronic EVP & President Mike Coyle to Speak at Piper Jaffray Healthcare Conference 184

9.4 Legal And Regulatory ................................................................................................................................... 184

9.4.1 Apr 11, 2014: Federal Court Orders Preliminary Injunction on U.S. Sales of Medtronic's Infringing Transcatheter Valve............................................................................................................................................... 184

9.4.2 Mar 12, 2014: Venaxis to Discuss Top-Line Results from Pivotal Study of APPY1 Test ........................ 185

9.4.3 Jan 22, 2014: Medtronic Statement on U.S. Supreme Court Ruling in Medtronic, Inc. v. Mirowski Family Ventures ................................................................................................................................................................ 185



Page 6

9.4.4 Oct 19, 2013: Medtronic Statement on Medical Device Security ............................................................. 186

9.4.5 Aug 16, 2013: Glancy Binkow & Goldberg Announces Class Action Lawsuit Against Orthofix International 187

9.4.6 Aug 01, 2013: Medtronic Notifies More Than 2,700 Patients Of Lost Records ....................................... 187

9.4.7 Jul 01, 2013: Bronstein, Gewirtz & Grossman, LLC Announces that a Securities Class Action has been Filed Against Medtronic, Inc. ................................................................................................................................. 187

9.5 Other Significant Developments ................................................................................................................... 188

9.5.1 Apr 16, 2014: Bard Declares Quarterly Dividend ..................................................................................... 188

9.5.2 Feb 13, 2014: Medtronic Announces Cash Dividend for Fourth Quarter of Fiscal Year 2014 ................ 188

9.5.3 Jan 28, 2014: Medtronic Relocates Its Regional Headquarters to Dubai ................................................ 188

9.5.4 Jan 08, 2014: BIOTRONIK Devices and Leads, including latest DX System Technology, Now Available for Veterans Affairs Clients .................................................................................................................................... 189

9.5.5 Dec 04, 2013: Medtronic Issues $500,000 in Health Access Grants to Support Diabetes Services for the Underserved of Greater Los Angeles .................................................................................................................... 189

9.5.6 Nov 27, 2013: Stereotaxis announces results of rights offering .............................................................. 191

9.5.7 Sep 03, 2013: SurModics Announces Organizational Changes .............................................................. 191

9.5.8 Aug 22, 2013: Medtronic Announces Cash Dividend for Second Quarter of Fiscal Year 2014 .............. 192

9.5.9 Jul 22, 2013: SurModics to Present at the InvestMNt Conference .......................................................... 192

9.6 Product News ............................................................................................................................................... 192

9.6.1 Feb 13, 2014: New Data Support Use of iRhythm's ZIO Service to Identify Cardiac Arrhythmias in Stroke and TIA Patients .................................................................................................................................................... 192

9.6.2 Jan 27, 2014: Laerdal Medical and Wolters Kluwer Health Introduce Virtual Simulation Learning Tool for Nursing Students ................................................................................................................................................... 193

9.6.3 Jan 02, 2014: ZIO Service Identifies Significantly More Cardiac Arrhythmias Than the Traditional Holter Monitor, According to Study Published Online in the American Journal of Medicine ........................................... 194

9.6.4 Dec 20, 2013: First-in-Man Implantation of CARMAT‘s Bioprosthetic Artificial Heart ............................. 195

9.6.5 Nov 15, 2013: FDA Classifies Medtronic's Worldwide Voluntary Field Action on Guidewires as Class I Recall 195

9.6.6 Oct 02, 2013: Synergy Pharmaceuticals Announces Plans to Initiate a Phase 2 Study of SP-333 for Opioid-Induced Constipation ................................................................................................................................. 196

9.6.7 Jun 25, 2013: nContact Continues To Expand Intellectual Property Portfolio For Its Multidisciplinary Approach For Treatment Of Cardiac Arrhythmias ................................................................................................. 197

9.7 Strategy And Business Planning .................................................................................................................. 197

9.7.1 Sep 17, 2013: Medtronic Opens New Customer Innovation Centre in Galway, Ireland .......................... 197

9.7.2 Sep 02, 2013: Medtronic announces formation of hospital solutions business aimed at driving efficiencies 198

9.7.3 Aug 29, 2013: Medtronic To Set Up Global Center Of Excellence In Singapore For Business Model Innovation .............................................................................................................................................................. 199

10 Appendix ........................................................................................................................................................... 200

10.1 Research Methodology ................................................................................................................................ 201

10.1.1 Coverage .............................................................................................................................................. 201

10.1.2 Secondary Research ............................................................................................................................ 201

10.1.3 Primary Research ................................................................................................................................. 202

10.1.4 Market Modeling and Forecasting ........................................................................................................ 203



Page 7

10.1.5 Company Share Analysis ..................................................................................................................... 206

10.1.6 Distribution Share Analysis .................................................................................................................. 207

10.2 Expert Panel ................................................................................................................................................. 207

10.3 GlobalData Consulting ................................................................................................................................. 208

10.4 Disclaimer ..................................................................................................................................................... 208

1.1 List of Tables

Table 1: Cardiac Rhythm Management Market, Cross Country Comparison, North America, Revenue ($m), USD Constant, 2005-

2020 ................................................................................................................................................................................................. 15

Table 2: Cardiac Rhythm Management Market, North America, Category Comparison by Revenue ($m), USD Constant, 2005-

2020 ................................................................................................................................................................................................. 17

Table 3: Cardiac Rhythm Management Market, North America, Revenue ($m), Historic, USD Constant, 2005-2012 ................... 19

Table 4: Cardiac Rhythm Management Market, North America, Revenue ($m), Forecast, USD Constant, 2012-2020 ................. 21

Table 5: Cardiac Rhythm Management Market, North America, Volume (Units), 2005-2020......................................................... 23

Table 6: Cardiac Rhythm Management Market, North America, Volume (Units), Historic, 2005-2012 ........................................... 25

Table 7: Cardiac Rhythm Management Market, North America, Volume (Units), Forecast, 2012-2020 ......................................... 27

Table 8: Cardiac Rhythm Management Market, North America, Company Share by Revenue ($m), USD Constant, 2011-2012 . 29

Table 9: Cardiac Rhythm Management Market, Canada, Revenue ($m), USD Constant, Historic, 2005-2012 ............................. 31

Table 10: Cardiac Rhythm Management Market, Canada, Revenue ($m), USD Constant, Forecast, 2012-2020 ......................... 33

Table 11: Cardiac Resynchronisation Therapy Market, Canada, Revenue ($m), USD Constant, Historic, 2005-2012 .................. 35

Table 12: Implantable Cardioverter Defibrillators Market, Canada, Revenue ($m), USD Constant, Historic, 2005-2012 ............... 37

Table 13: Pacemakers Market, Canada, Revenue ($m), USD Constant, Historic, 2005-2012 ....................................................... 39

Table 14: Cardiac Resynchronisation Therapy Market, Canada, Revenue ($m), USD Constant, Forecast, 2012-2020 ................ 41

Table 15: Implantable Cardioverter Defibrillators Market, Canada, Revenue ($m), USD Constant, Forecast, 2012-2020 ............. 43

Table 16: Pacemakers Market, Canada, Revenue ($m), USD Constant, Forecast, 2012-2020 ..................................................... 45

Table 17: Cardiac Rhythm Management Market, Canada, Volume (Units), Historic, 2005-2012 ................................................... 47

Table 18: Cardiac Rhythm Management Market, Canada, Volume (Units), Forecast, 2012-2020 ................................................. 49

Table 19: Cardiac Resynchronisation Therapy Market, Canada, Volume (Units), Historic, 2005-2012 .......................................... 51

Table 20: Implantable Cardioverter Defibrillators Market, Canada, Volume (Units), Historic, 2005-2012 ...................................... 53

Table 21: Pacemakers Market, Canada, Volume (Units), Historic, 2005-2012 ............................................................................... 55

Table 22: Cardiac Resynchronisation Therapy Market, Canada, Volume (Units), Forecast, 2012-2020 ........................................ 57

Table 23: Implantable Cardioverter Defibrillators Market, Canada, Volume (Units), Forecast, 2012-2020 .................................... 59

Table 24: Pacemakers Market, Canada, Volume (Units), Forecast, 2012-2020 ............................................................................. 61

Table 25: Cardiac Rhythm Management Market, Canada, Average Price ($), Historic, 2005-2012 ............................................... 62

Table 26: Cardiac Rhythm Management Market, Canada, Average Price ($), Forecast, 2012-2020 ............................................. 63

Table 27: Cardiac Rhythm Management Market, Canada, Distribution Share by Revenue ($m), USD Constant, 2011-2012 ....... 64

Table 28: Cardiac Rhythm Management Market, Canada, Company Share by Revenue ($m), USD Constant, 2011-2012 ......... 66

Table 29: Cardiac Rhythm Management Market, Mexico, Revenue ($m), USD Constant, Historic, 2005-2012 ............................ 68

Table 30: Cardiac Rhythm Management Market, Mexico, Revenue ($m), USD Constant, Forecast, 2012-2020 .......................... 70

Table 31: Cardiac Resynchronisation Therapy Market, Mexico, Revenue ($m), USD Constant, Historic, 2005-2012 ................... 72

Table 32: Implantable Cardioverter Defibrillators Market, Mexico, Revenue ($m), USD Constant, Historic, 2005-2012 ................ 74

Table 33: Pacemakers Market, Mexico, Revenue ($m), USD Constant, Historic, 2005-2012 ........................................................ 76



Page 8

Table 34: Cardiac Resynchronisation Therapy Market, Mexico, Revenue ($m), USD Constant, Forecast, 2012-2020 ................. 78

Table 35: Implantable Cardioverter Defibrillators Market, Mexico, Revenue ($m), USD Constant, Forecast, 2012-2020 .............. 80

Table 36: Pacemakers Market, Mexico, Revenue ($m), USD Constant, Forecast, 2012-2020 ...................................................... 82

Table 37: Cardiac Rhythm Management Market, Mexico, Volume (Units), Historic, 2005-2012 .................................................... 84

Table 38: Cardiac Rhythm Management Market, Mexico, Volume (Units), Forecast, 2012-2020 .................................................. 86

Table 39: Cardiac Resynchronisation Therapy Market, Mexico, Volume (Units), Historic, 2005-2012 ........................................... 88

Table 40: Implantable Cardioverter Defibrillators Market, Mexico, Volume (Units), Historic, 2005-2012 ........................................ 90

Table 41: Pacemakers Market, Mexico, Volume (Units), Historic, 2005-2012 ................................................................................ 92

Table 42: Cardiac Resynchronisation Therapy Market, Mexico, Volume (Units), Forecast, 2012-2020 ......................................... 94

Table 43: Implantable Cardioverter Defibrillators Market, Mexico, Volume (Units), Forecast, 2012-2020 ...................................... 96

Table 44: Pacemakers Market, Mexico, Volume (Units), Forecast, 2012-2020 .............................................................................. 98

Table 45: Cardiac Rhythm Management Market, Mexico, Average Price ($), Historic, 2005-2012 ................................................ 99

Table 46: Cardiac Rhythm Management Market, Mexico, Average Price ($), Forecast, 2012-2020 ............................................ 100

Table 47: Cardiac Rhythm Management Market, Mexico, Distribution Share by Revenue ($m), USD Constant, 2011-2012 ...... 101

Table 48: Cardiac Rhythm Management Market, Mexico, Company Share by Revenue ($m), USD Constant, 2011-2012 ......... 103

Table 49: Cardiac Rhythm Management Market, United States, Revenue ($m), USD Constant, Historic, 2005-2012 ................ 105

Table 50: Cardiac Rhythm Management Market, United States, Revenue ($m), USD Constant, Forecast, 2012-2020 .............. 107

Table 51: Cardiac Resynchronisation Therapy Market, United States, Revenue ($m), USD Constant, Historic, 2005-2012 ....... 109

Table 52: Implantable Cardioverter Defibrillators Market, United States, Revenue ($m), USD Constant, Historic, 2005-2012 .... 111

Table 53: Pacemakers Market, United States, Revenue ($m), USD Constant, Historic, 2005-2012 ............................................ 113

Table 54: Cardiac Resynchronisation Therapy Market, United States, Revenue ($m), USD Constant, Forecast, 2012-2020 ..... 115

Table 55: Implantable Cardioverter Defibrillators Market, United States, Revenue ($m), USD Constant, Forecast, 2012-2020 .. 117

Table 56: Pacemakers Market, United States, Revenue ($m), USD Constant, Forecast, 2012-2020 .......................................... 119

Table 57: Cardiac Rhythm Management Market, United States, Volume (Units), Historic, 2005-2012 ........................................ 121

Table 58: Cardiac Rhythm Management Market, United States, Volume (Units), Forecast, 2012-2020 ...................................... 123

Table 59: Cardiac Resynchronisation Therapy Market, United States, Volume (Units), Historic, 2005-2012 ............................... 125

Table 60: Implantable Cardioverter Defibrillators Market, United States, Volume (Units), Historic, 2005-2012 ........................... 127

Table 61: Pacemakers Market, United States, Volume (Units), Historic, 2005-2012 .................................................................... 129

Table 62: Cardiac Resynchronisation Therapy Market, United States, Volume (Units), Forecast, 2012-2020 ............................. 131

Table 63: Implantable Cardioverter Defibrillators Market, United States, Volume (Units), Forecast, 2012-2020.......................... 133

Table 64: Pacemakers Market, United States, Volume (Units), Forecast, 2012-2020 .................................................................. 135

Table 65: Cardiac Rhythm Management Market, United States, Average Price ($), Historic, 2005-2012 .................................... 136

Table 66: Cardiac Rhythm Management Market, United States, Average Price ($), Forecast, 2012-2020 .................................. 137

Table 67: Cardiac Rhythm Management Market, United States, Distribution Share by Revenue ($m), USD Constant, 2011-2012

....................................................................................................................................................................................................... 138

Table 68: Cardiac Rhythm Management Market, United States, Company Share by Revenue ($m), USD Constant, 2011-2012

....................................................................................................................................................................................................... 140

Table 69: Cardiac Rhythm Management Market Pipeline Products ............................................................................................. 143

Table 70 Total Number of Primary Research Participants, Cardiovascular Devices Market, by Country ..................................... 203

1.2 List of Figures

Figure 1: Cardiac Rhythm Management Market, Cross Country Comparison, North America, Revenue ($m), USD Constant,

2005-2020 ........................................................................................................................................................................................ 14



Page 9

Figure 2: Cardiac Rhythm Management Market, North America, Category Comparison by Revenue ($m), USD Constant, 2005-

2020 ................................................................................................................................................................................................. 16

Figure 3: Cardiac Rhythm Management Market, North America, Revenue ($m), Historic, USD Constant, 2005-2012 .................. 18

Figure 4: Cardiac Rhythm Management Market, North America, Revenue ($m), Forecast, USD Constant, 2012-2020 ................ 20

Figure 5: Cardiac Rhythm Management Market, North America, Volume (Units), 2005-2020 ....................................................... 22

Figure 6: Cardiac Rhythm Management Market, North America, Volume (Units), Historic, 2005-2012 ......................................... 24

Figure 7: Cardiac Rhythm Management Market, North America, Volume (Units), Forecast, 2012-2020 ....................................... 26

Figure 8: Cardiac Rhythm Management Market, North America, Company Share (%), 2012 ........................................................ 28

Figure 9: Cardiac Rhythm Management Market, Canada, Revenue ($m), USD Constant, Historic, 2005-2012 ............................ 30

Figure 10: Cardiac Rhythm Management Market, Canada, Revenue ($m), USD Constant, Forecast, 2012-2020 ........................ 32

Figure 11: Cardiac Resynchronisation Therapy Market, Canada, Revenue ($m), USD Constant, Historic, 2005-2012 ................. 34

Figure 12: Implantable Cardioverter Defibrillators Market, Canada, Revenue ($m), USD Constant, Historic, 2005-2012 ............. 36

Figure 13: Pacemakers Market, Canada, Revenue ($m), USD Constant, Historic, 2005-2012...................................................... 38

Figure 14: Cardiac Resynchronisation Therapy Market, Canada, Revenue ($m), USD Constant, Forecast, 2012-2020 ............... 40

Figure 15: Implantable Cardioverter Defibrillators Market, Canada, Revenue ($m), USD Constant, Forecast, 2012-2020 ........... 42

Figure 16: Pacemakers Market, Canada, Revenue ($m), USD Constant, Forecast, 2012-2020.................................................... 44

Figure 17: Cardiac Rhythm Management Market, Canada, Volume (Units), Historic, 2005-2012 .................................................. 46

Figure 18: Cardiac Rhythm Management Market, Canada, Volume (Units), Forecast, 2012-2020 ................................................ 48

Figure 19: Cardiac Resynchronisation Therapy Market, Canada, Volume (Units), Historic, 2005-2012 ........................................ 50

Figure 20: Implantable Cardioverter Defibrillators Market, Canada, Volume (Units), Historic, 2005-2012 ..................................... 52

Figure 21: Pacemakers Market, Canada, Volume (Units), Historic, 2005-2012 ............................................................................. 54

Figure 22: Cardiac Resynchronisation Therapy Market, Canada, Volume (Units), Forecast, 2012-2020 ...................................... 56

Figure 23: Implantable Cardioverter Defibrillators Market, Canada, Volume (Units), Forecast, 2012-2020 ................................... 58

Figure 24: Pacemakers Market, Canada, Volume (Units), Forecast, 2012-2020 ........................................................................... 60

Figure 25: Cardiac Rhythm Management Market, Canada, Company Share (%), 2012 ................................................................ 65

Figure 26: Cardiac Rhythm Management Market, Mexico, Revenue ($m), USD Constant, Historic, 2005-2012 ........................... 67

Figure 27: Cardiac Rhythm Management Market, Mexico, Revenue ($m), USD Constant, Forecast, 2012-2020 ......................... 69

Figure 28: Cardiac Resynchronisation Therapy Market, Mexico, Revenue ($m), USD Constant, Historic, 2005-2012 .................. 71

Figure 29: Implantable Cardioverter Defibrillators Market, Mexico, Revenue ($m), USD Constant, Historic, 2005-2012 ............... 73

Figure 30: Pacemakers Market, Mexico, Revenue ($m), USD Constant, Historic, 2005-2012 ....................................................... 75

Figure 31: Cardiac Resynchronisation Therapy Market, Mexico, Revenue ($m), USD Constant, Forecast, 2012-2020 ................ 77

Figure 32: Implantable Cardioverter Defibrillators Market, Mexico, Revenue ($m), USD Constant, Forecast, 2012-2020 ............. 79

Figure 33: Pacemakers Market, Mexico, Revenue ($m), USD Constant, Forecast, 2012-2020 ..................................................... 81

Figure 34: Cardiac Rhythm Management Market, Mexico, Volume (Units), Historic, 2005-2012 ................................................... 83

Figure 35: Cardiac Rhythm Management Market, Mexico, Volume (Units), Forecast, 2012-2020 ................................................. 85

Figure 36: Cardiac Resynchronisation Therapy Market, Mexico, Volume (Units), Historic, 2005-2012 .......................................... 87

Figure 37: Implantable Cardioverter Defibrillators Market, Mexico, Volume (Units), Historic, 2005-2012 ...................................... 89

Figure 38: Pacemakers Market, Mexico, Volume (Units), Historic, 2005-2012............................................................................... 91

Figure 39: Cardiac Resynchronisation Therapy Market, Mexico, Volume (Units), Forecast, 2012-2020 ........................................ 93

Figure 40: Implantable Cardioverter Defibrillators Market, Mexico, Volume (Units), Forecast, 2012-2020 .................................... 95

Figure 41: Pacemakers Market, Mexico, Volume (Units), Forecast, 2012-2020............................................................................. 97

Figure 42: Cardiac Rhythm Management Market, Mexico, Company Share (%), 2012 ............................................................... 102

Figure 43: Cardiac Rhythm Management Market, United States, Revenue ($m), USD Constant, Historic, 2005-2012 ............... 104



Page 10

Figure 44: Cardiac Rhythm Management Market, United States, Revenue ($m), USD Constant, Forecast, 2012-2020 ............. 106

Figure 45: Cardiac Resynchronisation Therapy Market, United States, Revenue ($m), USD Constant, Historic, 2005-2012 ...... 108

Figure 46: Implantable Cardioverter Defibrillators Market, United States, Revenue ($m), USD Constant, Historic, 2005-2012... 110

Figure 47: Pacemakers Market, United States, Revenue ($m), USD Constant, Historic, 2005-2012 ........................................... 112

Figure 48: Cardiac Resynchronisation Therapy Market, United States, Revenue ($m), USD Constant, Forecast, 2012-2020 .... 114

Figure 49: Implantable Cardioverter Defibrillators Market, United States, Revenue ($m), USD Constant, Forecast, 2012-2020. 116

Figure 50: Pacemakers Market, United States, Revenue ($m), USD Constant, Forecast, 2012-2020 ......................................... 118

Figure 51: Cardiac Rhythm Management Market, United States, Volume (Units), Historic, 2005-2012 ....................................... 120

Figure 52: Cardiac Rhythm Management Market, United States, Volume (Units), Forecast, 2012-2020 ..................................... 122

Figure 53: Cardiac Resynchronisation Therapy Market, United States, Volume (Units), Historic, 2005-2012.............................. 124

Figure 54: Implantable Cardioverter Defibrillators Market, United States, Volume (Units), Historic, 2005-2012 .......................... 126

Figure 55: Pacemakers Market, United States, Volume (Units), Historic, 2005-2012 .................................................................. 128

Figure 56: Cardiac Resynchronisation Therapy Market, United States, Volume (Units), Forecast, 2012-2020............................ 130

Figure 57: Implantable Cardioverter Defibrillators Market, United States, Volume (Units), Forecast, 2012-2020 ........................ 132

Figure 58: Pacemakers Market, United States, Volume (Units), Forecast, 2012-2020 ................................................................ 134

Figure 59: Cardiac Rhythm Management Market, United States, Company Share (%), 2012 ..................................................... 139

Figure 60: GlobalData Epidemiology-Based Forecasting Model .................................................................................................. 205

Figure 61: GlobalData Capital Equipment-Based Forecasting Model .......................................................................................... 206

Figure 62: Primary Interviews by Participant Type (%) ................................................................................................................. 207



Page 11

2 Introduction

Medical Equipment Market Reports are the ideal guide for anyone wishing to understand their market better in terms

of revenues, unit sales, distributors and competitors.

2.1 What Is This Report About?

This report provides an overview and the following information related to the country, region, various categories,

distribution share and competitive landscape in the market:

1. Comprehensive data related to the market revenue, unit sale, average price, company share and

distribution share.

2. Corporate-level profiles of key companies operating in the Cardiac Rhythm Management market, which

includes a brief overview of the company. The selection of the companies is based on their operational

presence.

3. A list of key products under development by different companies. The selection of this list is based on the

territory in which these products are being clinically investigated.

4. Key news and deals related to the Cardiac Rhythm Management market.

2.2 Cardiac Rhythm Management Market Segmentation

Cardiac Rhythm Management Devices market is segmented as described below, in this report:

1. Implantable Loop Recorders

2. Cardiac Resynchronisation Therapy

Cardiac Resynchronisation Therapy includes sub-segments such as Cardiac Resynchronisation

Therapy - Defibrillators and Cardiac Resynchronisation Therapy - Pacemakers

3. Implantable Cardioverter Defibrillators

Implantable Cardioverter Defibrillators includes Dual Chamber Implantable Cardioverter Defibrillators

and Single Chamber Implantable Cardioverter Defibrillators

4. Pacemakers

Pacemakers includes Dual Chamber Pacemakers and Single Chamber Pacemakers



Page 12

2.3 Definitions of Markets Covered in the Report

Cardiac Rhythm Management

Cardiac Rhythm Management (CRM) devices are used to restore the natural synchronized pumping rhythm of the

heart. These include pacemakers, Cardiac Resynchronization Therapy (CRT), Implantable Loop Recorders and

Implantable Cardioverter Defibrillators (ICD). These Devices are used for the treatment of congestive heart failure.

Cardiac Resynchronisation Therapy

Cardiac Resynchronization Therapy (CRT) device is used for the treatment of heart failure-induced conduction

disturbances and ventricular dysynchrony. When used in combination with stable, optimal medical therapy, CRT is

designed to reduce symptoms and improve cardiac function by restoring the mechanical sequence of ventricular

activation and contraction.

Cardiac Resynchronisation Therapy – Defibrillators

Cardiac Resynchronisation Therapy – Defibrillator uses an Implantable Cardioverter Defibrillator (ICD) to improve the

coordination of the heart rhythm. This device utilizes three leads, one to the right atrium and one in each of the

ventricles. One unit refers to one cardiac resynchronisation therapy - defibrillator. Leads and electrodes are not

included here.

Cardiac Resynchronisation Therapy – Pacemakers

Cardiac Resynchronisation Therapy – Pacemaker uses a pacemaker device to improve the coordination of the heart

rhythm. This device utilizes three leads, one to the right atrium and one in each of the ventricles. One unit refers to

one cardiac resynchronisation therapy - pacemaker. Leads and electrodes are not included here.

Implantable Cardioverter Defibrillators

An Implantable Cardioverter Defibrillator (ICD) is a device which detects cardiac arrhythmia, or irregular beating of the

heart, and delivers a high voltage shock to restore the natural rhythm. This restores the natural rhythm of the heart.

The ICD is of the single chamber and dual chamber.

Single Chamber Implantable Cardioverter Defibrillators

A single chamber Implantable Cardioverter Defibrillator (ICD) is a device which detects cardiac arrhythmia, or

irregular beating of the heart in one chamber (either an atrium or a ventricle) of the heart, and delivers a high voltage

shock to restore the natural rhythm. One unit refers to one single chamber implantable cardoverter defibrillator. Leads

and electrodes are not included here.

Dual Chamber Implantable Cardioverter Defibrillators

A dual chamber Implantable Cardioverter Defibrillator (ICD) is a device which detects cardiac arrhythmia, or irregular

beating of the heart in two chambers (the atrium or the ventricle) of the heart, and delivers a high voltage shock to

restore the natural rhythm. One unit refers to one dual chamber implantable cardioverter defibrillator. Leads and

electrodes are not included here.



Page 13

Pacemakers

A pacemaker is a device designed to regulate the beating of the heart by providing electrical impulses delivered by

the electrodes contacting the heart muscle. It can be a single chamber or dual chamber type.

Dual Chamber Pacemakers

Dual chamber pacemakers have pacing leads in two chambers of the heart. One lead paces the atrium and one

paces the ventricle. This approach more closely matches the natural pacing of the heart. These types of pacemaker

can co-ordinate function between the atria and ventricles. Leads and electrodes are not included here. One unit refers

to one dual chamber pacemaker.

Single Chamber Pacemakers

A single chamber pacemaker is a device which has a single pacing lead placed into a chamber of the heart. This

could be the atrium or ventricle. Leads and electrodes are not included here. One unit refers to one single chamber

pacemaker.

Implantable Loop Recorder (ILR)

An Implantable Loop Recorder (ILR) is a subcutaneous, single-lead, electrocardiographic (ECG) monitoring device

used for diagnosis in patients with recurrent unexplained episodes of palpitations or syncope, along with long-term

monitoring in patients at risk for or with atrial fibrillation, structural heart disease, bundle branch block, recurrent

neurally mediated syncope etc. It consists of the insertable recorder that comes with a battery and two surface

electrodes. One unit refers to a single implantable loop recorder.



Page 14

3 Cardiac Rhythm Management Market, North America

3.1 Cardiac Rhythm Management Market, North America, Revenue ($m), 2005-2020

Figure 1: Cardiac Rhythm Management Market, Cross Country Comparison, North America, Revenue ($m), USD

Constant, 2005-2020

Source: GlobalData



Page 15

Table 1: Cardiac Rhythm Management Market, Cross Country Comparison, North America, Revenue ($m), USD

Constant, 2005-2020

Country Name 2005 2012 2020 CAGR 05-12 CAGR 12-20 CAGR 05-20

Source: GlobalData



Page 16

3.2 Cardiac Rhythm Management Market, North America, Category Comparison by Revenue ($m), 2005-2020

Figure 2: Cardiac Rhythm Management Market, North America, Category Comparison by Revenue ($m), USD Constant,

2005-2020

Source: GlobalData



Page 17

Table 2: Cardiac Rhythm Management Market, North America, Category Comparison by Revenue ($m), USD Constant,

2005-2020

Category 2012 CAGR 05-12 CAGR 12-20

Source: GlobalData

T



Page 200

10 Appendix

The data and analysis within this report are driven by Medical eTrack. Medical eTrack gives you the key information

required to drive sales, investment and deal-making activity in your business. It includes the following:

15,000+ data tables showing market size across more than 780 medical equipment segments and 15 countries,

from 2005 and forecast to 2020

6,000+ primary expert interviews, conducted annually to ensure data and report quality

1,100+ medical equipment conference reports

1,000+ industry-leading reports per annum, covering growing sectors, market trends, investment opportunities

and competitive landscape

600+ analysis reports, covering market and pipeline product analysis, by indication; medical equipment trends

and issues, and investment and M&A trends worth over $3m

50,000+ medical equipment company profiles

2,000+ private, emerging and technology start-up company profiles

4,000+ company profiles of medical equipment manufacturers in China and India

2,000+ company profiles of medical equipment manufacturers in Japan

825+ companies‘ revenue splits and market shares

1,100+ quarterly and annual medical equipment company financials

700+ medical equipment company SWOTs

11,700+ pipeline product profiles

14,000+ marketed product profiles

16,900+ clinical trials

17,000+ trial investigators

18,000+ new product patents

3,700+ reports on companies with products in development

21,500+ reports on deals in the medical equipment industry

1,300+ surgical and diagnostic procedures by therapy area

50+ key healthcare indicators by country

For more information or to receive a free demonstration of the service, please visit:

http://www.medicaletrack.com/ContactUs.aspx?Id=RequestDemo



Page 201

10.1 Research Methodology

GlobalData‘s dedicated research and analysis teams consist of experienced professionals with advanced statistical

expertise and marketing, market research and consulting backgrounds in the medical devices industry.

GlobalData adheres to the codes of practice of the European Pharmaceutical Marketing Research Association

(http://www.ephmra.org/).

All GlobalData databases are continuously updated and revised.

10.1.1 Coverage

The objective of updating GlobalData‘s coverage is to ensure that it represents the most up-to-date vision of the

industry possible.

Changes to the industry taxonomy are built on the basis of extensive research of company, association and

competitor sources.

Company coverage is based on three key factors: revenue; product and media attention; and innovation and market

potential.

The estimated revenue of all major companies, both private and public, are gathered and used to prioritize coverage.

GlobalData aims to cover all major news events and deals in the medical devices industry, updated on a daily basis.

The coverage is further streamlined and strengthened with additional input from GlobalData‘s expert panel.

10.1.2 Secondary Research

The research process begins with extensive secondary research using internal and external sources to gather all

relevant data and information pertaining to a particular market model for a particular country. The secondary research

sources that are typically referred to include, but are not limited to:

Company websites, annual reports, financial reports, broker reports, investor presentations and SEC filings

Industry trade journals, scientific journals and other technical literature

Association and healthcare organization websites

PubMed, Medscape and other relevant services which compile extensive reviews of clinical literature

Internal proprietary databases

Relevant patent and regulatory databases

National government documents, statistical databases and market reports

Procedure registries

News articles, press releases and web-casts specific to the companies operating in the market



Page 202

10.1.3 Primary Research

GlobalData conducts interviews with industry participants and commentators in order to validate its data and analysis.

A typical research interview fulfills the following functions:

Provides first-hand information on market size, market trends, growth trends, competitive landscape and

future outlook

Helps to validate and strengthen secondary research findings

Further develops the analysis team‘s expertise and market understanding

Primary research involves email correspondence, telephone interviews and face-to-face interviews for each market,

category, segment and sub-segment across a range of geographies.

The participants who typically take part in such a process include, but are not limited to:

o Industry participants: CEOs, VPs, marketing/product managers, market intelligence managers and

national sales managers

o Distributors, paramedics and representatives from hospital stores, laboratories and pharmacies

o Outside experts: investment bankers, valuation experts and research analysts that specialize in specific

medical equipment markets

o Key opinion leaders: physicians and surgeons that specialize in the therapeutic areas in which the

medical device is used

The market data was validated based on the inputs from 1,771 primary research participants. The primary research

participants included stakeholders from demand side such as the cardiovascular surgeons, as well as participants

from the supply side such as the marketing managers, sales managers and product managers of companies

manufacturing/marketing cardiovascular devices.



Page 203

Table 70 Total Number of Primary Research Participants, Cardiovascular Devices Market, by Country

Country Total Number of Primary Research Participants

United States 136

United Kingdom 120

Germany 128

France 153

Italy 121

Spain 134

Brazil 128

China 79

India 173

Russia 89

Japan 88

Australia 122

Canada 111

Mexico 90

South Korea 99

Total 1,771

Source: GlobalData

10.1.4 Market Modeling and Forecasting

GlobalData uses an epidemiology-based treatment flow model and capital equipment-based model to estimate and

forecast market size.

Epidemiology-Based Market Model and Forecasting

The epidemiology-based forecasting model uses epidemiology data gathered from research publications and primary

interviews with physicians to establish the target patient population and treatment flow pattern for individual diseases

and therapies. The data covers prevalence, incidence, diseased population, diagnosed population, and treatment

population.

The market forecast begins with the general population, the size of which varies depending on the indication.

Prevalence is the percentage of the total population that suffers from a particular disease or condition.

Incidence is the number of new cases of a condition, symptom, death or injury that develop during a specific

time period, such as one year.

The diseased population is the population suffering from a particular disease or condition.

The diagnosed population is the population that has been diagnosed with a particular disease or condition,

expressed as a percentage of the prevalence population.

The treatment population is the percentage of the population that has been diagnosed with a particular

disease or condition.



Page 204

Device uptake is the percentage of the treatment population using a particular device, determined based on

the primary responses and the information available in secondary sources.

The epidemiology-based forecasting model for a medical device is used to:

Determine the patient segment using a particular device or procedure

Determine the frequency of usage of a particular device depending on the patient type, which further helps to

determine the absolute unit sales of a device in a year

The market for any medical device is directly proportional to the volume of units sold and the price per unit.

Market size = volumes of units sold X ASP (Average Selling Price)

The volume of units sold is calculated from the number of patients using or that has been implanted with the device.

Data on treatment rate, diagnosis and surgical treatment rate, if unavailable from research publications, is gathered

from interviews with physicians and used to estimate the patient volume for the disease under consideration.

The ASP of a device is mostly gathered from primary and secondary sources. ASP is the price at which a device is

available in a target country to an end-user. For capital equipment, the end-user is typically considered to be the

healthcare setting. For implants and consumables purchased by patients, the end-user is the patient.

Factors such as company share, reimbursement, company type (local/domestic or multinational) are taken into

consideration during ASP analysis, which uses the following sources:

Company websites

Annual reports/industry reports

Press releases



Page 205

Epidemiology-Based Forecasting Model

Capital Equipment-Based Market Model and Forecasting

The capital equipment-based forecasting model is based on the installed base, replacements and new sales of a

specific type of capital equipment in healthcare facilities such as hospitals, clinics and diagnostic centers. The

installed base is calculated from the average number of units per facility. Sales for a particular year are arrived at by

calculating the number of replacement units and new units (additional and first-time purchases). Secondary sources

and interviews with supply-side participants and key opinion leaders from healthcare facilities are used to arrive at

installed base and unit sales for a particular year. The factors typically affecting the forecast growth rates are:

Growth in the number of healthcare facilities

Healthcare spending and government programs and initiatives

Migration from low-end equipment to high-end equipment

Growth in the diagnosed population and treatment population

Figure 60: GlobalData Epidemiology-Based Forecasting Model

Source: GlobalData



Page 206

Capital Equipment-Based Forecasting Model

10.1.5 Company Share Analysis

Company shares are calculated by analyzing a company‘s sales in a particular market. In the case of public

companies, annual reports and regulatory filings, investor presentations, earnings call transcripts and broker reports

are used to determine a company‘s revenue in a particular market and in a particular geography.

In the case of the private companies, company share data is gathered mostly from primary interviews and secondary

sources. Company share analysis is based on primary interviews with:

Supply side (manufacturers)

Procurement side

Distributors

Hospital purchasing groups

Demand side (surgeons/specialists)

Figure 61: GlobalData Capital Equipment-Based Forecasting Model

Source: GlobalData



Page 207

The benefits of this approach are:

High number of respondents to validate and from which to derive accurate company shares

Broad view from the supply, demand, and procurement side

Prevents biased opinions being reproduced

Demand-side interviews with key opinion leaders help to understand their preferences for the devices of

specific companies, strengthening company share estimates

Primary Interviews by Participant Type

Figure 62: Primary Interviews by Participant Type (%)

The final company share data is based on input from the supply side, the procurement side and the demand side, as

well as secondary sources. Please note that market share for companies that are included under the ‗Others‘

category is not tracked on an individual basis.

10.1.6 Distribution Share Analysis

Distribution share information is gathered using a combination of secondary and primary research. It is supported by

primary interviews because the availability of secondary data is limited in most cases.

10.2 Expert Panel

GlobalData uses a panel of experts to cross-verify its databases and forecasts.

GlobalData‘s expert panel comprises marketing managers, product specialists, international sales managers from

medical device companies, academics from research universities, key opinion leaders from hospitals, consultants

from venture capital funds and distributors/suppliers of medical equipment and supplies.

Historic data and forecasts are relayed to GlobalData‘s expert panel for feedback and adjusted accordingly.

50

25

25

Procurement side Supply side Demand side



Page 208

10.3 GlobalData Consulting

We hope that the data and analysis in this brief will help you to make informed and imaginative business decisions. If

you have further requirements, GlobalData‘s consulting team may be able to help you. GlobalData offers tailor-made

analytical and advisory services to drive your key strategic decisions.

10.4 Disclaimer

All Rights Reserved.

No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form by any means,

electronic, mechanical, photocopying, recording or otherwise without the prior permission of the publisher,

GlobalData.

Documents

North America Cardiac Rhythm Management Market Outlook to … · Page 1 North America Cardiac Rhythm Management Market Outlook to 2020 Reference Code: GDMECR0090DB ... 9.2 Financial